CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non–ST-Segment Elevation Acute Coronary Syndrome Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease-Meta-Analysis and Meta-Regression of Randomized Trials 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Geometry as a Confounder When Assessing Ventricular Systolic Function: Comparison Between Ejection Fraction and Strain Impact of door-to-balloon time on long-term mortality in high- and low-risk patients with ST-elevation myocardial infarction Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
|<<... 27 28 29 30 31 32 33 ...>>|

Original Research

JOURNAL：CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高，冠状动脉通路是否良好对于后续的冠脉介入是个挑战，最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊

1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良（unfavorable coronary access）患者的冠脉介入成功率数据后发现：

1）TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003)，SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ；

2）提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜（THV）中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预（TAVR-in-TAVR）时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR：A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案，3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率（7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13）;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高（0.9%）；

2）通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞（delayed coronary occlusions），发生率为4.3%。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top